Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/2701| Title: | Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer |
| Authors: | Готько, Євген Степанович Peeters, Marc Jay Price, Timothy |
| Keywords: | KRAS and Antibody Testing, Panitumumab, FOLFIRI |
| Issue Date: | 1-Nov-2010 |
| Publisher: | JOURNAL OF CLINICAL ONCOLOGY |
| Series/Report no.: | VOLUME 28;NUMBER 31 |
| Abstract: | Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status. |
| Type: | Text |
| Publication type: | Стаття |
| URI: | https://dspace.uzhnu.edu.ua/jspui/handle/lib/2701 |
| ISSN: | 0732-183X |
| Appears in Collections: | Наукові публікації кафедри радіології та онкології |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| JCO-2010-Peeters-4706-13.pdf | Основна стаття | 366.8 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.